AG
FPRX

Aperio Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Aperio Group’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-7,932
Closed -$48K – 2937
2019
Q2 		$48K Sell
7,932
-6,008
-43% -$57.4K ﹤0.01% 2545
2019
Q1 		$187K Buy
13,940
+2,466
+21% +$28.1K ﹤0.01% 2177
2018
Q4 		$107K Buy
11,474
+762
+7% +$9.07K ﹤0.01% 2221
2018
Q3 		$149K Buy
+10,712
New +$159K ﹤0.01% 2223

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aperio Group's FPRX Position: Q3 2019 in Review

Aperio Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2019, closing a stake of 7,932 shares — an estimated $48K sold.

Aperio Group first reported a position in FPRX in Q3 2018 and held it in 4 quarters. The position peaked at $187K in Q1 2019. 103 funds tracked by Wall St. Rank hold FPRX as of Q3 2019.

  • Aperio Group reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 7,932 Five Prime Therapeutics, Inc. shares in Q3 2019, an estimated $48K.
  • Aperio Group first reported a position in Five Prime Therapeutics, Inc. in Q3 2018 and held it in 4 quarters.
  • Aperio Group's Five Prime Therapeutics, Inc. position peaked at $187K in Q1 2019.
  • 103 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.